The two-decade journey of Corin Holdings Limited through the orthopedics market, changing its portfolio and being taken into private equity, latterly under the ownership of Permira, has been nothing if not compelling. Not that the directors of the UK-based hip and knee arthroplasty specialist would have described it that way when the US metal-on-metal hip resurfacing issue in 2011 ended Stryker Corporation’s interest in hips, and thereby also its 10-year distribution agreement with Corin.
Corin had to look inwards, coming off the UK stock market, refinancing and assembling a new portfolio of technologies. It...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
